DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06877572

ECS Weight

Recruiting

Weight Loss Management in Endometrial Cancer Survivors

Enacting Active Survivorship: Implementation of Weight Management Strategies in Endometrial Cancer Survivors

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Enrollment

50

estimated

Study population

Obesity / overweight, Oncology

Key I/E criteria

•BMI ≥30•Female

Primary endpoint

•Percentage of participants referred to weight loss clinic who are able to start

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06877572
Org study IDSTUDY00160821

Timeline

Milestones

Study first posted2025-03-14actual
Study start2025-03-25actual
Last update posted2025-10-27actual
Primary completion2028-10estimated (month precision)
Study completion2030-10estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweightOncology

Eligibility

Who can enroll

Minimum age18 Years
SexFemale
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Survivors of low-risk early-stage endometrial cancer up to 36 months post primary treatment with body mass index (BMI) ≥30 kg/m\^2

Inclusion criteria

•≥18 years old
•ECOG 0-2
•BMI ≥ 30kg/m2
•Completed surgical staging with no evidence of residual disease
•Endometrioid endometrial adenocarcinoma, p53 wild type
•Stage 1
•Undergoing active surveillance +/- brachytherapy

Exclusion criteria

•Unable to participate in behavior weight loss
•Stroke, heart attack, end stage liver disease, or end stage kidney disease during the last 6 months.
•Currently on a GLP-1 agonist
•Currently on insulin

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
2
Glycemic / diabetes
1
Other clinical outcomes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in insulin resistance over 12 months using HgA1c as a surrogate marker in participants on weight loss medications

Time frame:12 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Patient-reported / QoL

2 endpoints
Secondary/protocol endpoint

Change in quality of life as assessed by the Functional Assessment of Cancer Therapy- Gynecology (FACT-G) over 12 months in participants on weight loss medications

Time frame:12 months

change from baseline, improvement

Secondary/protocol endpoint

Change in depression as assessed by Patient Health Questionnaire-2 (PHQ-2) over 12 months in participants on weight loss medications

Time frame:12 months

change from baseline, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

Percentage of participants referred to weight loss clinic who are able to start weight management medications

Time frame:12 months

threshold achievement, improvement

Publications (18)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.